
XAIR Stock Forecast & Price Target
XAIR Analyst Ratings
Bulls say
Beyond Air is a commercial-stage medical device and biopharmaceutical company that has developed a unique and precise delivery system utilizing nitric oxide from ambient air called LungFit. With its innovative product and technology, the company has potential to capitalize on the growing market for NO therapy, particularly in the treatment of respiratory diseases. The proposed acquisition of NeuroNOS adds another promising platform to Beyond Air's portfolio, demonstrating their commitment to growth and expansion through strategic partnerships. Additionally, the potential for significant monetary gain through milestone payments and equity ownership in the acquiring entity adds further value to the company.
Bears say
Beyond Air is undergoing a transition to drive commercialization and revenue generation, signaled by the replacement of former CEO Steve Lisi with Chief Commercial Officer Robert Goodman. This change suggests that the Board is pushing for a shift towards a story focused on commercial execution, customer deployment, and international expansion. The termination of a proposed agreement and potential divestiture of the NeuroNOS platform has no impact on the company's overall strategic objective, and management remains focused on advancing their core product LungFit. However, there are financial and operational risks to consider, including the company's reliance on third-party partnerships and their ability to successfully commercialize and expand in the market.
This aggregate rating is based on analysts' research of Beyond Air Inc and is not a guaranteed prediction by Public.com or investment advice.
XAIR Analyst Forecast & Price Prediction
Start investing in XAIR
Order type
Buy in
Order amount
Est. shares
0 shares